Hemolytic	hemolytic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
omeprazole	omeprazole	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Omeprazole	omeprazole	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
drug	drug	O	O	O	O
designed	designed	O	O	O	O
to	to	O	O	O	O
block	block	O	O	O	O
the	the	O	O	O	O
final	final	O	O	O	O
step	step	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
acid	acid	O	O	O	O
secretory	secretory	O	O	O	O
process	process	O	O	O	O
within	within	O	O	O	O
the	the	O	O	O	O
parietal	parietal	O	O	O	O
cell	cell	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
shown	shown	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
extremely	extremely	O	O	O	O
effective	effective	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
peptic	peptic	O	DISEASE	OTHERS	I
ulcer	ulcer	O	DISEASE	OTHERS	I
disease	disease	O	O	OTHERS	I
,	,	O	O	O	O
reflux	reflux	O	O	OTHERS	I
esophagitis	esophagitis	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
Zollinger-Ellison	zollinger-ellison	O	O	O	O
syndrome	syndrome	O	O	O	O
.	.	O	O	O	O

Although	although	O	O	O	O
clinical	clinical	O	O	O	O
experience	experience	O	O	O	O
with	with	O	O	O	O
omeprazole	omeprazole	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
still	still	O	O	O	O
limited	limited	O	O	O	O
,	,	O	O	O	O
many	many	O	O	O	O
controlled	controlled	O	O	O	O
studies	studies	O	O	O	O
have	have	O	O	O	O
established	established	O	O	O	O
the	the	O	O	O	O
short-term	short-term	O	O	O	O
safety	safety	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
drug	drug	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
serious	serious	O	O	O	O
short-term	short-term	O	O	O	O
adverse	adverse	O	O	O	O
reaction	reaction	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
omeprazole	omeprazole	CHEMICALS	O	OTHERS	I
:	:	O	O	O	O
hemolytic	hemolytic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
developed	developed	O	O	O	O
weakness	weakness	O	DISEASE	OTHERS	I
,	,	O	O	O	O
lethargy	lethargy	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
shortness	shortness	O	O	OTHERS	I
of	of	O	O	OTHERS	I
breath	breath	O	O	OTHERS	I
2	2	O	O	O	O
days	days	O	O	O	O
after	after	O	O	O	O
starting	starting	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
omeprazole	omeprazole	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Two	two	O	O	O	O
weeks	weeks	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
initiation	initiation	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
,	,	O	O	O	O
her	her	O	O	O	O
hematocrit	hematocrit	O	O	O	O
had	had	O	O	O	O
decreased	decreased	O	O	O	O
from	from	O	O	O	O
44.1	44.1	O	O	O	O
%	%	O	O	O	O
to	to	O	O	O	O
20.4	20.4	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
she	she	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
positive	positive	O	O	O	O
direct	direct	O	O	O	O
Coombs	coombs	O	O	O	O
antiglobulin	antiglobulin	O	O	O	O
test	test	O	O	O	O
and	and	O	O	O	O
an	an	O	O	O	O
elevated	elevated	O	O	O	O
indirect	indirect	O	O	O	O
bilirubin	bilirubin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

After	after	O	O	O	O
she	she	O	O	O	O
discontinued	discontinued	O	O	O	O
the	the	O	O	O	O
omeprazole	omeprazole	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
her	her	O	O	O	O
hemoglobin	hemoglobin	O	O	O	O
and	and	O	O	O	O
hematocrit	hematocrit	O	O	O	O
gradually	gradually	O	O	O	O
returned	returned	O	O	O	O
to	to	O	O	O	O
normal	normal	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
mechanism	mechanism	O	O	O	O
by	by	O	O	O	O
which	which	O	O	O	O
omeprazole	omeprazole	CHEMICALS	O	OTHERS	I
caused	caused	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
's	's	O	O	O	O
hemolytic	hemolytic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
is	is	O	O	O	O
uncertain	uncertain	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
physicians	physicians	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
alerted	alerted	O	O	O	O
to	to	O	O	O	O
this	this	O	O	O	O
possible	possible	O	O	O	O
adverse	adverse	O	O	O	O
effect	effect	O	O	O	O
.	.	O	O	O	O

